Approximately half of all cancer patients present with cachexia, a condition in which disease-associated metabolic changes lead to a severe loss of skeletal muscle mass. Working toward an integrated and mechanistic view of cancer cachexia, we investigated the hypothesis that cancer promotes mitochondrial uncoupling in skeletal muscle. We subjected mice to in vivo phosphorous-31 nuclear magnetic resonance (31P NMR) spectroscopy and subjected murine skeletal muscle samples to gas chromatography/mass spectrometry (GC/MS). The mice used in both experiments were Lewis lung carcinoma models of cancer cachexia. A novel ‘fragmented mass isotopomer’ approach was used in our dynamic analysis of 13C mass isotopomer data. Our 31P NMR and GC/MS results indicated that the adenosine triphosphate (ATP) synthesis rate and tricarboxylic acid (TCA) cycle flux were reduced by 49 and 22%, respectively, in the cancer-bearing mice (p<0.008; t-test vs. controls). The ratio of ATP synthesis rate to the TCA cycle flux (an index of mitochondrial coupling) was reduced by 32% in the cancer-bearing mice (p=0.036; t-test vs. controls). Genomic analysis revealed aberrant expression levels for key regulatory genes and transmission electron microscopy (TEM) revealed ultrastructural abnormalities in the muscle fiber, consistent with the presence of abnormal, giant mitochondria. Taken together, these data suggest that mitochondrial uncoupling occurs in cancer cachexia and thus point to the mitochondria as a potential pharmaceutical target for the treatment of cachexia. These findings may prove relevant to elucidating the mechanisms underlying skeletal muscle wasting observed in other chronic diseases, as well as in aging.

Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model / AA. Tzika; CC. Fontes-Oliveira; AA. Shestov; C. Constantinou; N. Psychogios; V. Righi; D. Mintzopoulos; S. Busquets; FJ. Lopez-Soriano; S. Milot; F. Lepine; MN. Mindrinos; LG Rahme; JM Argiles.. - In: INTERNATIONAL JOURNAL OF ONCOLOGY. - ISSN 1019-6439. - ELETTRONICO. - 43:3(2013), pp. 886-894. [10.3892/ijo.2013.1998]

Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model

RIGHI, VALERIA;
2013

Abstract

Approximately half of all cancer patients present with cachexia, a condition in which disease-associated metabolic changes lead to a severe loss of skeletal muscle mass. Working toward an integrated and mechanistic view of cancer cachexia, we investigated the hypothesis that cancer promotes mitochondrial uncoupling in skeletal muscle. We subjected mice to in vivo phosphorous-31 nuclear magnetic resonance (31P NMR) spectroscopy and subjected murine skeletal muscle samples to gas chromatography/mass spectrometry (GC/MS). The mice used in both experiments were Lewis lung carcinoma models of cancer cachexia. A novel ‘fragmented mass isotopomer’ approach was used in our dynamic analysis of 13C mass isotopomer data. Our 31P NMR and GC/MS results indicated that the adenosine triphosphate (ATP) synthesis rate and tricarboxylic acid (TCA) cycle flux were reduced by 49 and 22%, respectively, in the cancer-bearing mice (p<0.008; t-test vs. controls). The ratio of ATP synthesis rate to the TCA cycle flux (an index of mitochondrial coupling) was reduced by 32% in the cancer-bearing mice (p=0.036; t-test vs. controls). Genomic analysis revealed aberrant expression levels for key regulatory genes and transmission electron microscopy (TEM) revealed ultrastructural abnormalities in the muscle fiber, consistent with the presence of abnormal, giant mitochondria. Taken together, these data suggest that mitochondrial uncoupling occurs in cancer cachexia and thus point to the mitochondria as a potential pharmaceutical target for the treatment of cachexia. These findings may prove relevant to elucidating the mechanisms underlying skeletal muscle wasting observed in other chronic diseases, as well as in aging.
2013
Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model / AA. Tzika; CC. Fontes-Oliveira; AA. Shestov; C. Constantinou; N. Psychogios; V. Righi; D. Mintzopoulos; S. Busquets; FJ. Lopez-Soriano; S. Milot; F. Lepine; MN. Mindrinos; LG Rahme; JM Argiles.. - In: INTERNATIONAL JOURNAL OF ONCOLOGY. - ISSN 1019-6439. - ELETTRONICO. - 43:3(2013), pp. 886-894. [10.3892/ijo.2013.1998]
AA. Tzika; CC. Fontes-Oliveira; AA. Shestov; C. Constantinou; N. Psychogios; V. Righi; D. Mintzopoulos; S. Busquets; FJ. Lopez-Soriano; S. Milot; F. Lepine; MN. Mindrinos; LG Rahme; JM Argiles.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/134242
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 51
  • Scopus 75
  • ???jsp.display-item.citation.isi??? 69
social impact